OmarAlkharabshehMD

Oncology • Mobile, AL

Hematologic Oncology

Associate Professor - University of South Alabama Mitchell Cancer Institute specializing in blood cancers and disorders including Leukemia, Lymphoma & Multiple Myeloma.

Join to view full profile

Dr. Alkharabsheh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Alkharabsheh's full profile

Already have an account?

Office
1660 Spring Hill Ave
Mobile, AL 36604
Phone+1 251-665-8000

Fax+1 251-445-8378

Summary

Dr. Omar Alkharabsheh is a Hematologist and Medical Oncologist, specializing in blood cancers and disorders including Leukemia, Lymphoma, and Multiple Myeloma.

Omar Alkharabsheh, M.D. | USA Health

Dr. Omar Alkharabsheh serves as an associate professor interdisciplinary clinical oncology at the USA College of Medicine and a medical oncologist and hematolog

Education & Training

Mayo Clinic College of Medicine and ScienceFellowship, Advanced Hematology Fellowship, 2017 - 2018
McLaren Health Care/Greater Lansing/MSUFellowship, Hematology and Medical Oncology, 2014 - 2017
Hurley Medical Center/Michigan State UniversityResidency, Internal Medicine, 2011 - 2014
Jordan University of Science and Technology FOMClass of 2008

Certifications & Licensure

AL State Medical License 2018 - 2025
MN State Medical License 2016 - 2019
MI State Medical License 2011 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2019 Aug 29
Active, not recruiting
Phase 3
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2021 Mar 09
Active, not recruiting
Phase 3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Start of enrollment: 2023 Jan 10
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, Perspectives of Treating Versus Referring Physicians.
Rawan Atallah, Nausheen Ahmed, Fathima Ayoobkhan, Md Saiful Islam Saif, Emerson Logan
Transplantation and Cellular Therapy. 2024-09-01
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Mu...
Aimaz Afrough, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed
Cancers. 2023-10-09
2 citations
The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival.
Ashish Manne, Madhuri Mulekar, Daisy Escobar, Pranitha Prodduturvar, Yazan Fahmawi
Journal of Cancer Research and Therapeutics. 2023-10-03

Press Mentions

Alabama woman asks Congress to increase funding for bone marrow transplant programMarch 24th, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

External Links

University of South Alabama Healthhttps://www.usahealthsystem.com/providers/omar-alkharabsheh